Physician profile
Dyney Joseph
NPI 1720331440
$4,951.13
in general payments reported to CMS, 2019-2025
39 companies · $948 in 2025
The $948 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $390 · 2022: $1,237 · 2023: $1,451 · 2024: $926 · 2025: $948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,007 · Education: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,007.40 |
| Education | $316.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $783.14 | 2021-2025 | Xospata, Cresemba |
| Incyte Corporation | $428.65 | 2023-2025 | Monjuvi, Jakafi |
| Genzyme Corporation | $281.29 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.91 | 2022-2025 | Livtencity, Ninlaro |
| Sanofi-Aventis U.S. LLC | $238.81 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $180.37 | 2022-2024 | Clonoseq |
| Merck Sharp & Dohme LLC | $169.39 | 2021-2024 | Prevymis |
| Glaxosmithkline, LLC. | $167.25 | 2021-2025 | Ojjaara, Shingrix |
| Novartis Pharmaceuticals Corporation | $164.56 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $158.30 | 2021-2024 | Tavalisse, Rezlidhia |
| Celgene Corporation | $153.17 | 2022-2024 | Reblozyl |
| Alexion Pharmaceuticals, INC. | $146.38 | 2022-2025 | Ultomiris |
| Janssen Scientific Affairs, LLC | $144.85 | 2022-2024 | Darzalex |
| Karyopharm Therapeutics INC. | $136.95 | 2021-2025 | Xpovio |
| Seagen INC. | $127.65 | 2022-2023 | Adcetris |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $126.72 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $116.15 | 2025 | Breyanzi |
| Morphosys, US INC. | $113.03 | 2023 | Monjuvi |
| Abbvie INC. | $110.83 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $101.78 | 2022-2024 | |
| Janssen Biotech, INC. | $94.63 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Sobi, INC | $83.47 | 2022-2025 | |
| Legend Biotech USA INC. | $77.68 | 2023-2025 | Carvykti |
| Daiichi Sankyo INC. | $69.10 | 2024-2025 | Vanflyta |
| Acrotech Biopharma INC. | $65.85 | 2022 | |
| Menarini Silicon Biosystems, INC. | $61.64 | 2024-2025 | |
| Stemline Therapeutics INC. | $59.52 | 2024-2025 | Elzonris |
| Genentech USA, INC. | $42.68 | 2023-2024 | Polivy, Lunsumio, Columvi |
| Kyowa Kirin, INC. | $42.17 | 2023-2025 | Poteligeo |
| Cti Biopharma Corp. | $41.25 | 2022-2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $34.92 | 2021-2022 | |
| Pfizer INC. | $28.06 | 2022 | |
| Recordati_rare_diseases_inc. | $21.63 | 2023 | Sylvant |
| Regeneron Healthcare Solutions, INC. | $21.62 | 2025 | Lynozyfic |
| Invivyd INC | $19.24 | 2025 | Pemgarda |
| Syndax Pharmaceuticals, INC. | $19.04 | 2025 | |
| Lilly USA, LLC | $18.39 | 2023 | Jaypirca |
| Amgen INC. | $14.58 | 2023 | Blincyto |
| Epizyme, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dyney Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.